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Natasa Hlavacova and Damiela Jezova
Abstract
The mineralocorticoid hormone aldosterone has been investigated almost exclu-
sively with respect to cardiovascular function, as the main effects of aldosterone 
are related to water-electrolyte balance and the control of the blood pressure. This 
overview is focused on less traditional and long-time neglected effects of aldosterone 
on the brain and behavior. Preclinical studies by our research group brought evi-
dence on causal relationships between aldosterone and anxiety as well as aldosterone 
and depression-like behavior. Aldosterone was found to be anxiogenic and depresso-
genic in a rat model. Preclinical studies also indicate that aldosterone may be an early 
marker of depression onset. Aldosterone is known to be an important component of 
the stress response, and we have shown that its role is particularly important during 
early postnatal period in pups. Studies in patients with major depressive disorder 
revealed that an unfavorable therapy outcome is predicted by a higher salivary 
aldosterone/cortisol ratio. Our clinical studies showed that salivary aldosterone 
concentrations reflect the severity, duration of the depressive episode, and treatment 
outcome in patients with major depressive disorder. Moreover, the patients with 
depression fail to exert known daily rhythmicity of aldosterone release.
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1. Introduction
The mineralocorticoid hormone aldosterone is typically viewed as the principal 
regulator of sodium and potassium balance thus playing a major role in maintaining 
extracellular volume homeostasis. The classical genomic actions of aldosterone are 
mediated by mineralocorticoid receptor (MR). The MR and its kin, the glucocor-
ticoid receptor (GR), evolved from an ancestral corticoid receptor in a cyclostome 
(jawless fish) throughout gene duplication and divergence. Distinct orthologs of the 
MR and GR initially appeared in cartilaginous fishes, such as sharks, skates, rays, 
and chimeras. Aldosterone first appears in lungfish, lobe-finned fish that are fore-
runners of terrestrial vertebrates [1, 2]. The evolution of the relationship between 
aldosterone and MR likely occurred in response to dramatic changes associated with 
transition from aquatic to terrestrial life. In the ocean, aquatic organisms had the 
burden of fighting constant salt loading, whereas the prospect of a terrestrial exis-
tence presented the opposite problem, preventing their emergence from the sea. It 
is likely that the aldosterone-MR relationship was a part of the solution to maintain 
ion balance during this transition from water to land [3]. Further sequence diver-
gence of the MR and GR in terrestrial vertebrates led to emergence of aldosterone 
as a selective ligand for the MR [4]. The first studies with recombinant human MR 
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yielded an unexpected discovery [5] that human MR has strong binding affinities 
for several corticosteroids (aldosterone, cortisol, corticosterone, and 11-deoxycor-
ticosterone) and for progesterone. Although these steroids show similar affinity for 
human MR, transcriptional activation of human MR by these steroids is different. 
Compared to glucocorticoids, aldosterone is a stronger activator of the MR [6]. The 
ability of aldosterone to activate human, rat, and mouse MRs is complicated by the 
substantially higher concentration of glucocorticoids.
Given the fact the glucocorticoids circulate at much higher concentrations than 
aldosterone, glucocorticoids would be expected to predominantly occupy the MRs 
under most conditions [7]. In the peripheral epithelial tissues, the specificity of MR for 
aldosterone is achieved by the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-
HSD2) which converts glucocorticoids to inactive metabolites, thus allowing aldoste-
rone to bind to the MR. In the brain, the situation is much more complicated. Central 
action of aldosterone via MR is limited due to almost negligible levels of 11β-HSD2 in 
the brain. The lack of 11β-HSD2 in MR-rich regions suggests that the majority of brain 
MRs are likely to be fully occupied by glucocorticoids [8]. From these reasons, possible 
central effects of aldosterone have been neglected for a long time. Nevertheless, over 
the last 20 years, there is growing body of evidence that certain brain areas contain 
MRs that bind preferentially mineralocorticoids. This was demonstrated in the nucleus 
tractus solitarius, the subcommissural organ, and the ventrolateral subdivision of the 
ventromedial nucleus of the hypothalamus [9–13]. Importantly, nonclassical effects of 
aldosterone mediated via nongenomic actions [14] and de novo synthesis of aldoste-
rone within the brain should also be considered [15].
Studies by Ron De Kloet group published more than 30 years ago were not in 
favor of aldosterone effects on exploratory activity or forced extinction paradigm 
of a passive avoidance response in rats [16]. Pretreatment with aldosterone blocked 
the serotonin response to corticosterone [17]. It should be noted, however, that 
aldosterone was administered in a single injection to acutely adrenalectomized rats. 
The authors concluded that that the time interval between acute aldosterone admin-
istration and behavioral testing (1 hr) was too long for the appearance of behavioral 
effects of aldosterone. Until 2008, nothing was known about repeated or chronic 
aldosterone treatment on behavior related to anxiety or depression in normal intact 
rodents.
Writing this overview was motivated by the new evidence on atypical effects of 
aldosterone gathering during the last few years, when we have started our research 
on aldosterone and the brain. In spite of the generally accepted view on the absence 
of the central effect of aldosterone, we have decided to perform research in the 
field. The main focus of this mini-review is given on aldosterone action in the 
central nervous system from two points of view, namely, the pathophysiology of 
mood disorders from translational point of view and the significance of aldosterone 
during the development.
2. Nothing dared nothing won
The scientific work is based on testing the hypotheses formulated on the basis of 
thoroughly verified facts obtained in several laboratories using various experimen-
tal approaches. It might happen, however, that even not yet satisfactory confirmed 
evidence evokes the desire to lead the research in a new direction. This happened to 
us, and we have to formulate a hypothesis on anxiogenic and depressogenic action 
of aldosterone about 10 years ago. At that time, the arguments to formulate such a 
hypothesis were rather vague and certainly inadequate, but we were full of enthusi-
asm and courage.
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Our scientific interest in atypical effects of aldosterone on mental functions 
was motivated by scattered data published 15 years ago by the authors Murck et al. 
[18] and Emanuele et al. [19]. In small groups of depressed patients, they observed 
increased plasma aldosterone concentrations. However, causal relationship between 
aldosterone and mood disorders has not been approached. Our first original data on 
this topic were obtained in animal studies.
In the first series of experiments, we have tested the hypothesis that prolonged 
elevation of circulating aldosterone induces increased anxiety-like behavior in rats. 
Subchronic treatment with aldosterone (2 μg/100 g body weight/day for 2 weeks) 
via subcutaneous osmotic minipumps was applied to induce a mild hyperaldo-
steronism. Rodents do not, of course, tell the researchers that they feel anxious, 
but there are behavioral tests in which anxiety level can be assessed. In these tests, 
we have shown that aldosterone-treated animals exhibited increased anxiety-like 
behavior [20]. Anxiogenic effect of aldosterone was manifested by a significantly 
reduced frequency of entries and time spent in the open arms in the elevated plus 
maze test as well as reduced number of entries and time spent in the central area of 
the open-field test in aldosterone-treated rats compared to controls. Aldosterone 
treatment negatively influenced both the conventional spatiotemporal measures 
of anxiety and the ethological parameters related to anxiety and risk assessment 
behavior [20].
The role of aldosterone in anxiety-like behavior was supported by the results 
obtained using a different approach, demonstrating an anxiolytic action of an aldo-
sterone antagonist. As an aldosterone antagonist, the selective MR blocker eplere-
none, a clinically used drug for the treatment of heart failure and hypertension, 
was used [21]. Mild anxiolytic effects were observed after a single administration 
of eplerenone at the dose of 100 mg/kg body weight [22]. Anxiolytic effects of MR 
blockade were completely demonstrated following repeated treatment with eplere-
none [23]. Eplerenone administered for 11 days (50 mg/kg body weight twice daily) 
influenced ethological indicators of anxiety. More importantly, significant differ-
ences were found in classical spatiotemporal measures, as the eplerenone-treated 
rats entered more often and spent more time in the open arms of the elevated plus 
maze. Another original finding is the effect of subchronic MR blockade on hippo-
campal concentrations of brain-derived neurotrophic factor (BDNF), a marker of 
brain plasticity. Stress-induced alterations in BDNF have been identified as a strong 
candidate modulating stress-related pathology [24, 25]. On the contrary, chronic 
treatment with antidepressants was shown to increase BDNF levels [26]. We have 
demonstrated that eplerenone treatment prevented stress-induced decrease in hip-
pocampal concentrations of BDNF, suggesting a positive influence of MR blockade 
on brain plasticity [23].
In the next series of experiments, we focused our attention on depression-like 
behavior. We have used the same rat model of hyperaldosteronism previously 
and assessed symptoms of depressive behavior using the sucrose preference test 
and the forced swim test. The results clearly demonstrated that the subchronic 
increase in circulating aldosterone exerts depressogenic effects [27]. Aldosterone 
treatment induced an anhedonic state manifested by decreased sucrose preference. 
Depressogenic action of aldosterone was confirmed also in the forced swimming 
test. Animals treated with aldosterone spent significantly longer time in immobility 
and showed significantly decreased latency to become immobile [27]. Our results 
on depression-like behavior induced by aldosterone treatment in rats were con-
firmed by the authors Bay-Richter et al. [28]. As a result of our collaboration with 
colleagues from the USA, we revealed that hyperaldosteronism induces changes in 
expression of genes that have been shown to be associated with a major depressive 
disorder in humans [27].
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Supporting data on the role of aldosterone in the development of depressive 
behavior have also been obtained in another animal model of depression. We have 
established a new and novel animal model of depression based on diet-induced 
tryptophan depletion in female rats [29]. Diet-induced tryptophan depletion 
resulted in a significant reduction of brain serotonin and induction of depression-
like behavior manifested by increased immobility in the forced swim test [30]. 
Interestingly, the depression-like state was associated with a significant increase 
in serum aldosterone concentrations. We showed that aldosterone secretion had 
increased already after 4 days of tryptophan depletion, prior to the rise in serum 
corticosterone. This finding suggests that aldosterone may be more important than 
corticosterone in the development of a depression-like state and aldosterone may 
constitute an early marker for the onset of depression-like behavior [30].
In a very recent study by Geerling et al. [13], the authors characterized a hall-
mark of aldosterone-sensitive HSD2 neurons in the nucleus of the solitary tract. 
They showed that axons of HSD2 neurons project to the parabrachial complex/
pre-locus coeruleus and the ventrolateral bed nucleus of the stria terminalis, two 
neural hubs with a crucial function in salt appetite (salt hunger) and accompanying 
arousal. They suggested that downstream targets of HSD2 neurons promote sodium 
appetite, but they may also influence stress coping and mood circuits to produce 
dysphoric, anhedonic, and anorexic symptoms of hyperaldosteronism.
Our evidence of a causal relationship between hyperaldosteronism and anxiety- 
and depression-like behaviors in animals represents a breakthrough in the research 
on aldosterone action in the central nervous system and reveals a new area of 
research with potential clinical significance.
3. Translation of experimental data to clinical research
Animal models can be useful tools in biomedical research, but undoubtedly, it 
has frequently been observed that effects found in animal models cannot be trans-
lated to the clinic [31]. It is therefore essential that knowledge gained from animal 
studies should be carefully confirmed in human studies.
To be able to translate the knowledge obtained in animal models to clinical 
research, we have initially introduced a methodology to measure aldosterone concen-
trations in saliva [32]. Determination of steroids in saliva has become a valuable alter-
native due to the noninvasiveness and laboratory independence of sampling. While 
assays for salivary cortisol are widely used, the availability of assays for measurement 
of aldosterone in saliva has been limited. Concentrations of aldosterone in saliva 
represent approximately one-third of the total level in plasma, and they correlate 
well with plasma values [33, 34]. We have modified the methodology of aldosterone 
radioimmunoassay by concentrating the saliva and validated the method by a low-
dose ACTH test and by confirmation of daily rhythm and sex differences [35].
We have provided the first original data on the relationship between aldosterone 
and trait anxiety in humans. We have shown that the relationship between aldoste-
rone and trait anxiety is determined by sex and the phase of the menstrual cycle in 
women [32]. Negative correlation between salivary aldosterone concentrations and 
trait anxiety was observed in women in the luteal phase, while a positive association 
was found in women in the follicular phase of the menstrual cycle.
In recent years, we have performed several studies to clarify the role of aldo-
sterone in depressive disorder. We have conducted a pilot study in patients with 
a major depressive disorder in collaboration with Marburg University, Germany. 
Biomarkers of MR function were examined in order to characterize their rela-
tionship to clinical treatment outcome after 6 weeks in 30 patients with major 
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depression [36, 37]. Although the number of patients was not very high, there was a 
significant association between salivary aldosterone concentrations and the severity 
of depressive symptoms. A negative correlation between aldosterone concentrations 
in saliva and improvement in clinical state of patients was revealed. Interestingly, a 
higher ratio of aldosterone to cortisol concentrations at baseline was predictive for 
poorer clinical outcome after 6 weeks of treatment [36].
Supporting data came also from other researcher groups. In patients with pri-
mary hyperaldosteronism, a higher occurrence of anxiety and depressive symptoms 
compared to healthy volunteers was demonstrated [38–40]. A population study 
in humans revealed that the combination of the chronic stress of living alone and 
depressive symptomatology was accompanied by high levels of aldosterone [41]. On 
the other hand, Hallberg et al. [42] found lower concentrations of aldosterone in 
patients with major depression with suicidal behavior than suicidal patients without 
depression and non-suicidal depressive patients.
The most complete results so far have been obtained by examining 60 patients with 
major depressive disorder in a study performed in collaboration with clinical psy-
chiatrists, particularly the Department of Psychiatry, Faculty of Medicine, Comenius 
University and University Hospital Bratislava, Slovakia [43]. The sample consisted of 37 
postmenopausal women and 23 men suffering from major depressive disorder. Morning 
and evening samples of saliva were obtained during depressive episode (admission to 
the hospital) and after reaching clinical remission (discharge). Results showed several 
notable original findings. Salivary aldosterone concentrations were higher at the time of 
admission to the hospital than those at the time of discharge, i.e., after improvement of 
the clinical state. It is well known that aldosterone secretion shows a daily rhythm [35, 
44, 45] with the highest values in the morning and the lowest at evening. The patients 
with depression failed to exert known daily rhythmicity of aldosterone release [43]. An 
intriguing finding was the observation of the relationship between morning aldoste-
rone concentrations and the duration of the current depressive episode. When patients 
were stratified according to the length of the depressive episode, women with a shorter 
duration of the depressive episode (up to 12 weeks) exhibited significantly higher 
aldosterone concentrations than women with a longer episode (over 16 weeks). In men, 
this difference was not observed. We have also demonstrated that morning salivary 
aldosterone concentrations are particularly higher in patients with severe depressive 
episode than those with moderate depressive episode. These findings strongly support 
the role of aldosterone in the pathophysiology of depressive disorder. Concentrations of 
aldosterone in the saliva appear to reflect the clinical outcome, duration, and severity of 
depressive episode in a sex-dependent manner [43].
4. Aldosterone during the development
In pups, the main physiological role of the renin-angiotensin-aldosterone 
system is to maintain water-electrolyte balance, while the hypothalamic-pituitary-
adrenocortical (HPA) axis regulates energy metabolism. Prenatal and early postnatal 
brain development is a very complex process that can be endangered by a number 
of endogenous and exogenous stimuli. This is a serious problem given the neurode-
velopmental background of several psychiatric disorders [46, 47]. Environmental 
stimuli that may interfere with the normal development of the central nervous 
system include excessive exposure to stressful situations. Exposure to stressors at 
the time of brain development may cause a repeated elevation in concentrations of 
glucocorticoids which are known to exert negative effects. Of the stress hormones, 
the neurotoxic effect is attributed, in particular, to glucocorticoids. Increased levels 
of glucocorticoids adversely affect neurogenesis and brain plasticity [25].
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As was already mentioned, animal models represent a useful tool in the research 
in the field of neurodevelopmental disorders. Long time ago, scientists have 
discovered that there is a physiological mechanism in the rodents protecting the 
developing brain from neurotoxic glucocorticoids. During the first 2 weeks of life 
(from about days 2–14), rat pups show reduced capacity to secrete corticosterone 
in response to several stimuli [48–50]. This period was called the stress non-
responsive period. Later, after introducing more sophisticated analytical methods 
for plasma corticosterone analysis, it has been found that a small increase occurred 
and the period was renamed to stress hyporesponsive period. In this period, cor-
ticosterone response to stress stimuli is several times lower than that in adult rats. 
This phenomenon is associated with dramatically reduced corticosteroid-binding 
globulin (CBG) levels [51, 52]. This occurs as a result of reduced half-life of CBG in 
plasma and decreased CBG production by the liver in the neonates [53, 54]. Thus, 
corticosterone circulates mainly in the free form during the stress hyporesponsive 
period, since CBG levels are negligible. During the stress hyporesponsive period, 
the adrenal gland is hyporesponsive to adrenocorticotropic hormone. Numerous 
studies have demonstrated that maternal factors, such as maternal care and feed-
ing, are critical for the regulation of the pup’s HPA axis and the maintenance of the 
stress hyporesponsive period [50]. It has been demonstrated that maternal depriva-
tion during the stress hyporesponsive period causes a rapid rise in corticosterone 
concentrations [50] and profoundly affects GR epigenetics [55]. This type of studies 
would be welcome for aldosterone and the MR as well, since these are understudied. 
No information on possible similar reduction of aldosterone in response to stressors 
during the stress hyporesponsive period was available.
In a joint project with the Institute of Experimental Medicine, Hungarian 
Academy of Sciences, we have demonstrated that 10-day rat pups showed increased 
rather than reduced response of aldosterone to several acute stress stimuli. Stress-
induced rise in aldosterone concentrations was significantly higher in pups com-
pared to that in adulthood as well as compared to the rise in corticosterone [56]. 
In adult rats, the response was quite opposite; the increase in stress-induced aldo-
sterone concentrations was only mild, whereas the elevation of corticosterone was 
much more pronounced. The physiological significance of increased aldosterone 
secretion during stress in the early postnatal period is supported by our findings 
of altered expression of mineralocorticoid and glucocorticoid receptors in the 
hypothalamus, hippocampus, and prefrontal cortex and in particular by increased 
expression of 11β-HSD2 [56].
It may be suggested that the main physiological importance of higher aldoste-
rone secretion in pups is related to the maintenance of water-electrolyte balance 
during the perinatal period. MRs are present in the heart, blood vessels, adipocytes, 
and macrophages. It is possible to assume that during the perinatal period, aldoste-
rone takes over the regulatory role of glucocorticoids in certain cellular processes 
and molecular mechanisms. Experiments in vasopressin-deficient Brattleboro 
rats excluded the possible important role of vasopressin. It appears that the shift 
from a more pronounced aldosterone to corticosterone rise during stress occurs 
after 40 postnatal days [57]. It is therefore clear that during rodent development, 
aldosterone is the more important stress hormone of the adrenal cortex than 
corticosterone.
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